Availability of new drugs Jevtana, Xtandi and Zytiga + earlier, stronger docetaxel gives about 2 years extra life

[JimJimJimJim]

Jim Marshall (not a doctor) said ...

These doctors knew that their metastatic castrate resistant patients were living longer with the new drugs available.

So they looked at their records:

Half the men treated in 2006 - 2009 were alive 10.6 months after treatment began; and

Half the men treated in 2009 - 2012 were alive 32.5 months after treatment began.

The two groups were separated by those with Jevtana (cabazitaxel), Xtandi (enzalutamide) and Zytiga (abiraterone) available, or not available.

The later group also had earlier use, and higher doses of Taxotere (docetaxel).

... end Jim

Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC).

 

Caution

This extract was published in association with the American Society of Clinical Oncology 2013 annual conference. Though the research behind it may have been excellent, your doctor cannot yet give much weight to it for a number of reasons, including:

• It is only an extract. The full paper may reveal information important for your treatment.
• The study has not yet had peer review - with doctors and researchers scrutinising the study closely for mistakes and limitations after it is published in a professional journal.
•  Your doctor may already be aware of a limitations of the findings because of their wider reading.

The link below is to a page or document that we do not control.
Parts of it may be wrong or misleading.
Check with your doctor if something interests you.
If it is temporarily or permanently unavailable, you may receive an error message.

 

http://meetinglibrary.asco.org/content/114884-132